Sandra Von MeierHead Business Development & Licensing at Debiopharm International SASpeaker
As Head of Business Development and Licensing at Debiopharm,Sandra is responsible for all business development and licensing activities at Debiopharm, covering both in licensing and out licensing activities, including all transactions. This year, Sandra closed the in-licensing of a USP inhibitor from Novo Nordisk/Forma as well as a multi-asset partnership with SunRock to develop novel HER/HER3 ADCs to add to Debiopharm`s oncology pipeline and a recent collaboration with Repare.
Before joining Debiopharm, Sandra was working as Senior Director Business Development & Licensing at Bayer responsible for oncology asset search, evaluation and transaction including the recent M&A with Vividion Therapeutics. Before Bayer, as Director Business Development Oncology at Merck KGaA, Sandra led numerous transactions, including the strategic collaboration for Xevinapant, including deals with F-star/bispecific antibodies, Vertex/DDR portfolio and Pfizer for Bavencio/avelumab. Sandra started her career at Medigene, a publicly listed German biotechnology company, where she also closed several transactions including the commercialization agreement with Astellas for Eligard.
Sandra studied Biochemistry at the FU Berlin and then moved to London for her Diploma at the Institute of Cancer Research. She holds a PhD from University College London.